Another study aimed to investigate the impact of concomitant TP53 mutations and their clinicopathological characteristics in ALK-rearranged NSCLC patients, as well as the association of TP53 with the effect of crizotinib in ALK-rearranged patients. This evidence concerns the gene TP53 and non-small cell lung carcinoma.